Client News

Novogenia AG Invests in State-of-the-Art Healthcare and Manufacturing Technologies at Its New Hallwang Headquarters

Darwin AG becomes Novogenia AG, strengthening its international position

Formycon AG and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars

Axxam and HeartBeat.bio partner to advance human-relevant cardiovascular drug discovery and cardiac safety assessment

Abivax Announces Closing of $920 Million Public Offering

AFYREN announces the resumption of production at its plant after the successful technical shutdown

REPRONOVO ANNOUNCES FIRST PARTICIPANT DOSED IN EU PHASE 2 TRIAL OF RPN-002 FOR EMBRYO IMPLANTATION

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)

Rentschler Biopharma appoints Dr. Torsten Woehr as Chief Executive Officer

Abivax announces trading resumption of its ordinary shares on Euronext Paris